Gene Therapy for Adenosine Deaminase Deficiency
- 1 February 2000
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 51 (1) , 33-47
- https://doi.org/10.1146/annurev.med.51.1.33
Abstract
The clinical gene therapy trials for adenosine deaminase (ADA) deficiency have defined both the potential benefits and the present limitations of gene therapy with hematopoietic stem cells (HSC). Current clinical results indicate that (a) both umbilical cord blood and neonatal bone marrow HSC can be transduced with murine retroviral-based vectors, (b) the transduced HSC can engraft in nonmyeloablated patients, (c) the frequency of HSC transduction/engraftment is low (1/10,000), (d) an in vivo selective advantage can exist for transduced T lymphoid progeny, and (e) the transduced ADA gene is not expressed in nondividing T lymphocytes. Improving the clinical results of gene therapy for ADA deficiency and other genetic diseases involving HSC will require (a) developing new vectors that express the transduced gene in nondividing cells and (b) increasing the frequency of stable HSC transduction.Keywords
This publication has 37 references indexed in Scilit:
- Retroviral Transfer of the Glucocerebrosidase Gene into CD34+ Cells from Patients with Gaucher Disease: In Vivo Detection of Transduced Cells without MyeloablationHuman Gene Therapy, 1998
- A quantitative ranking system for relating genotype to phenotype in adenosine deaminase (ADA) deficiency, based on the expressed activity of 29 mutant alleles in E. coliMolecular Immunology, 1998
- Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients. National Institutes of Health, Bethesda, MarylandHuman Gene Therapy, 1997
- Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiencyNature Genetics, 1996
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integraseCell, 1995
- Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors.Journal of Clinical Investigation, 1994
- Ex Vivo Gene Therapy of Familial Hypercholesterolemia. Howard Hughes Medical Institute, University of MichiganHuman Gene Therapy, 1992
- An in Vivo Model of Somatic Cell Gene Therapy for Human Severe Combined ImmunodeficiencyScience, 1991
- Combined immunodeficiency disease associated with adenosine deaminase deficiency: Report on a Workshop Held in Albany, New York, October 1, 1973The Journal of Pediatrics, 1975